TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02917200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: Oral route

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: Oral route

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: Oral route

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: Oral route

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: Oral route

Intervention type: OTHER
Group type: OTHER
Intervention: Negative control
Description: Oral route

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative control
Description: Oral route
Study: NCT02655354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Elements

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Management

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Anti-depressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Anti-depressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Anti-depressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Anti-depressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Anti-depressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Anti-depressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Anti-depressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Anti-depressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Sleep medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: Sleep medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Sleep medication
Study: NCT01768962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once Daily Application of TFV RG 1% Gel - Vaginal
Description: Vaginal application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once Daily Application of TFV RG 1% gel - Rectal
Description: Rectal application
Study: NCT02818452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal + OatWell28XF
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal + OatWell28XF
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal + OatWell28XF
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal
Study: NCT01768962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once Daily Application of TFV RG 1% gel - Rectal
Description: Rectal application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once Daily Application of TFV RG 1% Gel - Vaginal
Description: Vaginal application
Study: NCT02818452

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hot cereal
Study: NCT02363218

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife
Description: Patients will undergo a CT scan with and without contrast and MRI scan for radiation treatment planning and target delineation.SBRT will be delivered on the CyberKnife with Synchrony Respiratory Tracking capabilities. The tumor will be tracked with 3 implanted fiducial seeds for targeting. Treatment will be delivered in 3 fractions within a 7 day window at the discretion of the investigator.
Study: NCT00406367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (Xeomin)
Description: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, up to 50 Units per eye; Mode of administration: intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
Study: NCT00933023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: 1%hydrocortisone topical once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: Betamethasone 0.1% topical once daily for 8weeks
Study: NCT04022538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior maxillary vertical segmental sandwich osteotomy with simultaneous implant placement
Description: Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~* The first implant osteotomy will be prepared and placed while a chisel is placed between the down fractured segment and the basal bone, and then the second implant will be installed.~* The gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~* Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior maxillary vertical segmental sandwich osteotomy using micro-plates fixation
Description: Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~* The created gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~* The mobilized segment is to be fixed to the basal bone using micro-plates and micro-screws.~* Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material.
Study: NCT00006721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tositumomab
Description: Given IV
Study: NCT00215982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
Study: NCT04387916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KC1036
Description: Part 1: Dose-escalation phase , KC1036 10mg\~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3\~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.
Study: NCT04593771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG-PPD
Description: BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
Study: NCT00215982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered at a dose of 130 mg/m2 IV over 120 minutes in 250-500 ML D5W on day 1, every 42 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered at a dose of 180mg/m2 IV over 90 minutes on day 21 every 42 days.
Study: NCT01018888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auro KPro (Keratoprosthesis)
Description: Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
Study: NCT03980795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Participants met with an exercise physiologist at their monthly center appointment over a 3-month period (4 meetings). The consultations took place either together or separate from or with the dietitian's consultation (depending on appointment logistics). In addition the Exercise Physiologists telephone called each intervention participant on a weekly basis.
Study: NCT02755467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KTP laser
Description: Dual Wavelength Laser Emitting 532 nm Laser Energy
Study: NCT04396262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-1
Description: HTD-blueberry beverage with white bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-2
Description: Sweetened water with white bread as a control.
Study: NCT04021914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnChroma glasses
Description: Each participant will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life. They will be encouraged to wear the glasses for at least 10 hours over 1-2 weeks prior to wearing them in a clinical setting to adjust to their use, and for 10 minutes before beginning patient care as per manufacturer instructions. They will be encouraged to take specific note of clinical scenarios that require the use of color vision (e.g., - rashes, tympanic membrane erythema, stool guaiac testing, etc.).
Study: NCT01915602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refametinib (BAY86-9766)
Description: Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006)
Description: Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
Study: NCT03403140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week
Study: NCT02375360

Intervention type: OTHER
Intervention: Oral immunotherapy

Intervention type: OTHER
Intervention: Oral immunotherapy

Intervention type: OTHER
Intervention: Oral immunotherapy
Study: NCT04593771

Intervention type: DRUG
Group type: OTHER
Intervention: BCG-PPD
Description: BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
Study: NCT04767269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cuminum Cyminum
Description: Cuminum Cyminum mouthwash in chronic gingivitis patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: herbal Mouthwash
Description: herbal mouthwash in chronic gingivitis patients
Study: NCT01038583

Intervention type: DRUG
Intervention: 100 mg enteric-coated aspirin
Description: 100 mg enteric-coated aspirin, taken daily
Study: NCT03873714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipeline™ Vantage Embolization Device with Shield Technology™
Description: Pipeline™ Vantage Embolization Device with Shield Technology™
Study: NCT04673032

Intervention type: DEVICE
Intervention: Radiofrequency Ablation
Description: Radiofrequency Ablation for treatment of chronic pain
Study: NCT01038583

Intervention type: DRUG
Intervention: Placebo
Description: 100 mg enteric-coated placebo
Study: NCT04559295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate
Description: The intradiscal delivery of bone marrow concentrate (BMC) into discs, facet , epidural space, and sacroiliac joints
Study: NCT02102490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study: NCT04345471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg
Description: once daily dosing for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg
Description: once daily dosing for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily dosing for 8 weeks
Study: NCT01114113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pancelipase/placebo
Description: ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical trigger meals and will not be given for the initial baseline non-trigger and baseline trigger meal. In both of these arms, patients will also be swallowing the SmartPill Capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pancelipase/placebo
Description: ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical trigger meals and will not be given for the initial baseline non-trigger and baseline trigger meal. In both of these arms, patients will also be swallowing the SmartPill Capsule.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill capsule
Description: Measurement of a baseline, non-trigger meal intestinal transit by using the SmartPill capsule.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill capsule
Description: Measurement of intestinal transit of a trigger meal baseline by using the SmartPill capsule

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill capsule
Description: SmartPill capsule

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SmartPill capsule
Description: SmartPill capsule
Study: NCT02476552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Oral Capsules (Labeled)
Description: Single 300 mg dose of niraparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib IV (Labeled)
Description: Intravenous (IV) infusion of 100 μg niraparib (containing approximately 1 μCi of \[14C\]-niraparib)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Oral Capsules (Unlabeled)
Description: Single 300 mg dose of niraparib (unlabeled active pharmaceutical ingredient)
Study: NCT04476732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraben-free skincare product
Description: Paraben-free lotion will be applied twice a day for one week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraben-containing skincare product
Description: Paraben-containing lotion will be applied twice a day for one week.
Study: NCT04561310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post facilitation stretch
Description: Post facilitation stretch with maitland mobilization Grade I \& II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active release technique
Description: Active release technique with maitland mobilization Grade I \& II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session
Study: NCT02480010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
Study: NCT02141178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Study: NCT00875719

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen concentrators versus constant flow axygen
Description: Each patient performed 2 walking tests, and received oxygen supplementation from a portable concentrator or a liquid oxygen source, in a random order.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen concentrator
Description: comparison walk distance and saturation with continuous oxygen compared to intermittent oxygen
Study: NCT03896490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Training
Description: Infants watch interactive cartoons that respond to infants' direction of gaze. An eye-tracker records the infant's eye movements in real time, relaying this information to the computer. These presentations trigger motivating stimuli (cartoon animations with child-friendly sounds) every time the infant fulfills the demands of a task (e.g. when the infant looks at a character on the screen avoiding to be distracted by other objects moving across the screen). The length of training sessions varies depending on infants' engagement with stimuli and time criteria.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control procedure involves presentation of cartoons on a screen, while infants' gaze direction is recorded using the same eye-tracker and camera. The crucial difference is that the cartoons in this case are not interactive, thus do not change depending on infants' gaze direction. To ensure presentations in the control procedure are similar in length to those of the intervention group, infants in the control group are matched infant-by-infant and visit-by-visit with participants in the ACT treatment group: Infants in the control group see a replay of the session of the matched treated infant. Therefore, while the presentation is exactly the same (i.e. same length and same stimuli) for the treated and the control child, in the latter case the presentation is not interactive (i.e. not generated contingently on the infants' visual behaviour).
Study: NCT02233790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
Study: NCT02978235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS4464
Description: Intravenous (IV) Infusion
Study: NCT02599987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POWERbreathe® Classic Light
Description: Inspiratory Muscle Training

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: POWERbreathe® Classic Light
Description: Inspiratory Muscle Training
Study: NCT00685347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI
Description: 1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Albuterol
Description: 1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI
Study: NCT03553784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group delivered Low Intensity Cognitive Behavioural Therapy
Description: The intervention is group-delivered, low-intensity CBT similar to that used in IAPT (Improving Access to Psychological Therapies) Services in England. This intervention is already being offered as part of standard care at the Intervention site, and will not be altered by the study protocol, other than the requirement to complete a few more questionnaires. The intervention group meets weekly for eight weeks, and is facilitated by a clinical psychologist, a psychological well-being practitioner and a clinical nurse specialist from the medical oncology team. Content of the intervention is broad CBT, combining aspects of second-wave CBT, with elements of Narrative Therapy and ACT.
Study: NCT03518697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise program
Description: The exercise program is planned as a low-threshold exercise program with low barriers to participate. Patients will be asked about their interests and preferences of sports activities to conceive the exercise program together with the patients.
Study: NCT02383121

Intervention type: DRUG
Intervention: Midodrine
Description: Not appliciable
Study: NCT02033499

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SMBG
Description: Blood glucose levels are tested once daily.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SMBG
Description: Blood glucose levels are tested once daily.
Study: NCT01881100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resin infiltration
Description: The test group (41 children) had caries lesions treated with the resin infiltration technique using Icon by the following procedure: rubber dam applying; etching with 15% hydrochloric acid for 120 s; surface rinsing and drying; dehydrating with ethanol for 30 s and air-drying; infiltrant resin infiltration with a syringe for 180 s; resin polymerization (polymerized by blue light - wavelength of 450 nm and intensity of 800mW/cm2; resin reapplication for 60 s and polymerization; rubber dam removal, and working on the infiltrated lesion with polishing rubbers. After the procedure fluoride varnish was applied.